Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NovoTTF-200A with Chemoradiation in Newly Diagnosed GBM
NCT03780569Unknown
- Sponsor
- NovoCure
- Start
- Apr 2017
- Primary completion
- Jan 2019
- Countries
- 1
01
Overview
Open-label, single-arm trial, sponsored by NovoCure. Primary endpoint: Incidence of Radiotherapy treatment delays at 2 years. Status: unknown.
Beyond the preview
Go deeper on NCT03780569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03780569.